Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced that safety and efficacy ...

9th Military Vision Symposium on Novel Technology and Vision Restoration hosted by Harvard Medical School Department of Ophthalmology and Mass Eye and Ear, February 27-28, 2025, at the Starr Center ...

This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after ...

Patients with advanced kidney cancer who received an experimental vaccine after their tumors were removed were still ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

The ranibizumab injection could be administered in a convenient schedule twice per year for the treatment of diabetic macular ...

Microlenses applied to eyeglasses can help reduce growth-related worsening of nearsightedness (myopia), preventing potential ...

Previous research has shown that voretigene neparvovec administered subretinally early in childhood for RPE65-mediated ...

Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.

AI-powered research on one of the largest eye studies to date has created the most detailed maps of the retina ever produced.

Feb. 04, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease ...

Feb. 04, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease ... 48th ...